featured
2022 Top Story in Oncology: Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer—DESTINY-Breast04
- Written by
-
Ilana
Schlam
MD, FACP
-
Sara
M.
Tolaney
MD, MPH
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
- DeSantis CE, Ma J, Gaudet MM, et al. Breast Cancer Statistics, 2019. CA Cancer J Clin. 2019;69(6):438-451.
- Swain SM, Baselga J, Kim SB, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015;372(8):724-734.
- Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154.
- Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-2122.
- Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, Pathological, and PAM50 Gene Expression Features of HER2-Low Breast Cancer. NPJ Breast Cancer. 2021;7(1):1.
- Gampenrieder SP, Rinnerthaler G, Tinchon C, et al. Landscape of HER2-Low Metastatic Breast Cancer (MBC): Results From the Austrian AGMT_MBC-Registry. Breast Cancer Res. 2021;23(1):112.
- de Calbiac O, Lusque A, Mailliez A, et al. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France. JAMA Netw Open. 2022;5(9):e2231170.
- Gianni L, Lladó A, Bianchi G, et al. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2010;28(7):1131-1137.
- Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. J Clin Oncol. 2020;38(5):444-453.
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20.
Disclosure statements are available on the authors' profiles: